Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results
Rhea-AI Summary
Intuitive (Nasdaq: ISRG) reported preliminary unaudited results: Q4 2025 revenue ~$2.87B (+19% YoY) and FY2025 revenue ~$10.06B (+21% YoY). Full‑year da Vinci procedures totaled ~3,153,000 (+18% YoY) and the company placed 1,721 da Vinci systems in 2025 (including 870 da Vinci 5); Q4 placements were 532 systems (303 da Vinci 5). Instruments & accessories revenue was ~$1.66B in Q4 and ~$6.02B for FY2025. Preliminary results include a $70M fourth‑quarter contribution to the Intuitive Foundation. The company expects da Vinci procedures +13%–15% in 2026. Results are unaudited and subject to final closing and audit.
Positive
- FY revenue +21% to ~$10.06B
- Da Vinci procedures +18% to ~3,153,000 in 2025
- System placements +13% to 1,721 da Vinci systems in 2025
- Da Vinci 5 adoption: 870 placements in 2025 vs 362 in 2024
Negative
- Ion placements -28% to 195 in 2025 (271 in 2024)
- Q4 Intuitive Foundation expense increased to $70M from $45M
- Preliminary unaudited results subject to adjustment on audit
News Market Reaction – ISRG
On the day this news was published, ISRG declined 2.68%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $5.48B from the company's valuation, bringing the market cap to $199.16B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ISRG traded down 1.91% with most close peers also slightly negative (e.g., ALC -2.79%, RMD -2.21%, BDX -0.56%). Momentum scanners did not flag a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Regulatory clearance | Positive | -1.5% | FDA cleared expanded indications for the da Vinci SP system. |
| Oct 21 | Quarterly earnings | Positive | +0.9% | Q3 2025 revenue and procedures grew strongly year over year. |
| Oct 08 | Product upgrade | Positive | +1.6% | FDA cleared AI-driven navigation and imaging upgrades for Ion. |
| Oct 07 | Financing news | Positive | -1.9% | Jupiter Endovascular closed an oversubscribed Series B financing. |
| Sep 12 | Product features | Positive | -1.4% | Intuitive introduced real-time surgical insights for da Vinci 5. |
Recent positive product, regulatory, and earnings updates have often seen mixed or negative next-day price reactions, indicating a tendency toward divergence on good news.
Over the last five news events since Sep 2025, Intuitive has consistently reported positive developments: new da Vinci 5 software features, AI-enabled Ion upgrades, and expanded FDA indications for da Vinci SP. Financially, Q1–Q3 2025 earnings showed strong double‑digit revenue and procedure growth with expanding installed base and ongoing share repurchases. Despite this, price reactions frequently diverged from the upbeat tone, with several strong updates followed by modest declines, framing today’s robust preliminary 2025 results in a context of cautious trading responses.
Market Pulse Summary
This announcement outlines robust preliminary Q4 and full‑year 2025 performance, with revenue of about $2.87B for the quarter and $10.06B for the year, supported by roughly 18–19% procedure growth. System placements, especially da Vinci 5, increased meaningfully, reinforcing installed‑base expansion seen in earlier 2025 earnings. Investors may watch the final audited results, detailed margin commentary, and 2026 procedure guidance of 13–15% to gauge how this growth trajectory translates into profitability and capital allocation going forward.
Key Terms
endoluminal medical
operating lease arrangements financial
usage-based operating lease arrangements financial
AI-generated analysis. Not financial advice.
SUNNYVALE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2025 financial results ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Financial and Operational Highlights
- Fourth quarter 2025 worldwide procedures (da Vinci and Ion combined) grew approximately
18% compared with the fourth quarter of 2024. Da Vinci procedures grew approximately17% and Ion procedures grew approximately44% . Average da Vinci system utilization increased4% in the fourth quarter of 2025 as compared with the fourth quarter of 2024, primarily driven by adoption of da Vinci 5 in the U.S. and continued growth in utilization in OUS markets. - Full year 2025 worldwide procedures (da Vinci and Ion combined) grew approximately
19% compared with 2024. Da Vinci procedures grew approximately18% and Ion procedures grew approximately51% . The Company expects worldwide da Vinci procedures to increase approximately13% to15% in 2026 as compared with 2025. - During the fourth quarter of 2025, the Company placed 532 da Vinci surgical systems, compared with 493 in the fourth quarter of 2024. The fourth quarter 2025 da Vinci surgical system placements included 303 da Vinci 5 systems, compared with 174 in the fourth quarter of 2024. During the fourth quarter of 2025, the Company placed 42 Ion endoluminal systems, compared with 69 in the fourth quarter of 2024.
- During 2025, the Company placed 1,721 da Vinci surgical systems, compared with 1,526 systems in 2024. The 2025 da Vinci surgical system placements included 870 da Vinci 5 systems, compared with 362 in 2024. During 2025, the Company placed 195 Ion endoluminal systems, compared with 271 in 2024.
- Preliminary fourth quarter 2025 revenue of approximately
$2.87 billion increased by19% compared with$2.41 billion in the fourth quarter of 2024. Preliminary 2025 revenue of approximately$10.06 billion increased by21% compared with$8.35 billion in 2024. - Fourth quarter 2025 expenses included a
$70 million contribution to the Intuitive Foundation compared to a$45 million contribution to the Intuitive Foundation in the fourth quarter of 2024.
Preliminary Results
The Company expects fourth quarter 2025 revenue of approximately
Preliminary fourth quarter 2025 instruments and accessories revenue increased by
Fourth quarter 2025 da Vinci procedures increased approximately
Preliminary fourth quarter 2025 systems revenue was approximately
The Company placed 532 da Vinci surgical systems, of which 303 were da Vinci 5 systems, in the fourth quarter of 2025, compared with 493 systems, of which 174 were da Vinci 5 systems, in the fourth quarter of 2024. The fourth quarter 2025 da Vinci surgical system placements included 250 systems placed under operating lease arrangements, of which 150 systems were placed under usage-based operating lease arrangements, compared with 222 systems placed under operating lease arrangements, of which 140 systems were placed under usage-based operating lease arrangements in the fourth quarter of 2024.
The Company placed 1,721 da Vinci surgical systems, of which 870 were da Vinci 5 systems, in 2025, compared with 1,526 systems, of which 362 were da Vinci 5 systems, in 2024. The 2025 da Vinci surgical system placements included 872 systems placed under operating lease arrangements, of which 496 systems were placed under usage-based operating lease arrangements, compared with 776 systems placed under operating lease arrangements, of which 467 systems were placed under usage-based operating lease arrangements in 2024.
Commenting on the announcement, Intuitive CEO Dave Rosa said, “We are pleased with our strong performance in the final quarter of 2025 and the full year. In 2025, we saw increased adoption and utilization of our surgical platforms, expanded product clearances and indications for use across geographies, and more than 3.1 million da Vinci procedures performed. As always, we remain focused on delivering the goals we share with our customers, centered on improving patient care and outcomes.”
Additional unaudited preliminary revenue and procedure information has been posted to the Investor Relations section of the Intuitive website at: https://isrg.gcs-web.com/.
The Company is scheduled to present at the J.P. Morgan Healthcare Conference on January 14, 2026, at 9:00 a.m. PST. The Company is scheduled to report its fourth quarter 2025 results during a conference call on January 22, 2026, at which point the Company will discuss the 2025 financial results in more detail. Dial-in and webcast access information for both of these events are also available in the Investor Relations section of the Intuitive website.
About Intuitive
Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical systems and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where diseases are identified early and treated quickly, so patients can get back to what matters most.
Product and brand names/logos are trademarks or registered trademarks of Intuitive or their respective owners. See www.intuitive.com/trademarks.
For more information, please visit the Company’s website at www.intuitive.com.
Forward-Looking Statements
The Company has not filed its Annual Report on Form 10-K for the year ended December 31, 2025. Accordingly, all financial results described in this press release should be considered unaudited preliminary results and are subject to change to reflect any corrections or adjustments, or changes in accounting estimates, that are identified prior to the time that the Company is in a position to complete these filings. Actual results could differ materially from these preliminary results.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to expectations concerning matters that are not historical facts. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” “goals,” “seeks,” “potential,” “targeted,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of the Company’s management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements include, but are not limited to, statements related to the Company’s unaudited preliminary financial and operational results for the fourth quarter and full year 2025, expected procedure growth in 2026, and the Company’s expectations regarding its strategic priorities, future market opportunities, and continued focus on customer goals and patient outcomes. These forward-looking statements should be considered in light of various important factors, including, but not limited to, the following: completion of the Company’s final closing procedures, final adjustments, and other developments that may arise in the course of audit and review procedures, the overall macroeconomic environment, which may impact customer spending and the Company’s costs, including tariffs, the levels of inflation, and interest rates; the conflict between Ukraine and Russia; conflicts in the Middle East; disruption to the Company’s supply chain, including difficulties in obtaining a sufficient supply of materials; curtailed or delayed capital spending by hospitals; the impact of global and regional economic and credit market conditions on healthcare spending; delays in obtaining new product approvals, clearances, or certifications from the U.S. Food and Drug Administration (“FDA”), comparable regulatory authorities, or notified bodies; the risk of the Company’s inability to comply with complex FDA and other regulations, which may result in significant enforcement actions; regulatory approvals, clearances, certifications, and restrictions or any dispute that may occur with any regulatory body; healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and customer acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; the Company’s completion of and ability to successfully integrate acquisitions; intellectual property positions and litigation; risks associated with the Company’s operations and any expansion outside of the U.S.; unanticipated manufacturing disruptions or the inability to meet demand for products; the Company’s reliance on sole and single sourced suppliers; the results of legal proceedings to which the Company is or may become a party; adverse publicity regarding the Company and the safety of the Company’s products and adequacy of training; the impact of changes to tax legislation, guidance, and interpretations; changes in tariffs, trade barriers, and regulatory requirements (including changes to tariffs imposed by the U.S. on imports from various countries, including Mexico, where the Company currently manufactures a significant majority of its instruments and accessories, Germany, where the Company currently manufactures a majority of its endoscopes, and China, where the Company currently imports certain materials); and other risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those risk factors identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company’s other filings with the Securities and Exchange Commission. The Company’s actual results may differ materially and adversely from those expressed in any forward-looking statement, and the Company undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.
Contact: Investor Relations
(408) 523-2161
FAQ
What were Intuitive (ISRG) preliminary Q4 2025 revenues and YoY change?
How many da Vinci procedures did ISRG report for full year 2025?
How many da Vinci systems did ISRG place in 2025 and how many were da Vinci 5?
What guidance did Intuitive give for da Vinci procedures in 2026?
How did Intuitive's instruments & accessories revenue perform in 2025?
Are these Intuitive (ISRG) results final and audited?
